Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27543270 | 1.00 | — | — | |
| SCHEMBL651400 | 0.97 | — | — | |
| Bromide SCHEMBL28672008 | 0.95 | — | — | |
| Benzene SCHEMBL15387790 | 0.92 | LPO (0.46) | — | |
| Hydrochloric Acid SCHEMBL820275 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL19970393 | 0.70 | TLR8 (0.76) | — | |
| SCHEMBL308400 | 0.69 | LPO (0.55) | — | |
| SCHEMBL27692875 | 0.69 | TLR8 (0.40) | — | |
| SCHEMBL17327411 | 0.69 | — | — | |
| Hydrochloric Acid SCHEMBL20975093 | 0.69 | FDPS (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577227-B2 | WDR5 inhibitors and modulators | VANDERBILT UNIVERSITY (US) | 2026-03-17 | — | — | US | disclosed |
| US-11999716-B2 | WDR5 inhibitors and modulators | VANDERBILT UNIVERSITY (US) | 2024-06-04 | — | — | US | disclosed |
| WO-2023090829-A1 | LOW-MOLECULAR-WEIGHT COMPOUND FOR REGULATING MLL1-WDR5 INTERACTION AND USE THEREOF | 엘젠테라퓨틱스 주식회사 | 2023-05-25 | — | — | WO | disclosed |
| US-20230038929-A1 | Fused Tricyclic Heterocyclic Compounds and Uses Thereof | Verge Analytics, Inc. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230012362-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2023-01-12 | — | — | US | disclosed |
| EP-4069699-A1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PIKFYVE KINASE USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISEASES | Verge Analytics, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| WO-2022169882-A1 | METHODS AND TREATMENT OF VIRAL INFECTION CAUSED BY SARS-COV-2 | Verge Analytics, Inc. (US) | 2022-08-11 | — | — | WO | disclosed |
| US-20220242849-A1 | WDR5 INHIBITORS AND MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-08-04 | — | — | US | disclosed |
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | E-THERAPEUTICS PLC (GB) | 2021-08-05 | — | — | US | disclosed |
| WO-2021113633-A1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PIKFYVE KINASE USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISEASES | Verge Analytics, Inc. (US) | 2021-06-10 | — | — | WO | disclosed |
| EP-0378255-B1 | 2-Aminopyrimidinone derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1994-04-27 | — | — | EP | disclosed |
| US-5284854-A | Antiserotonin. antihistamine agents; for sleep disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-02-08 | — | — | US | disclosed |
| US-5256659-A | Antiserotonine agents, antihistamines for nervous system disorders or psychological disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-10-26 | — | — | US | disclosed |
| US-5140029-A | Administering for nervous system, sleep or psychotic disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-08-18 | — | — | US | disclosed |
| US-5008268-A | Antiallergens | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-04-16 | — | — | US | disclosed |
| EP-0378254-A2 | 2-Aminopyrimidinone derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-07-18 | — | — | EP | disclosed |
| EP-0009362-B1 | HETEROCYCLIC DERIVATIVES OF GUANIDINE, THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS COMPRISING THEM | McNeilab, Inc. (US) | 1984-06-27 | — | — | EP | disclosed |
| EP-0029663-B1 | N-ARYL-N'-IMIDAZOL-2-YLUREAS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | McNeilab, Inc. (US) | 1984-04-18 | — | — | EP | disclosed |
| US-4265900-A | HYPOTENSIVE, ANTISECRETORY, ANTIDIARRHEA | MCNEILAB, INC. (US) | 1981-05-05 | — | — | US | disclosed |
| US-4182865-A | HYPOGLYCEMIC AGENTS | MCNEIL LABORATORIES, INC. (US) | 1980-01-08 | — | — | US | disclosed |